Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more
Shanghai Hile Bio-tech (603718) - Total Liabilities
Latest total liabilities as of September 2025: CN¥105.96 Million CNY
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has total liabilities worth CN¥105.96 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Hile Bio-tech - Total Liabilities Trend (2011–2024)
This chart illustrates how Shanghai Hile Bio-tech's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Hile Bio-tech Competitors by Total Liabilities
The table below lists competitors of Shanghai Hile Bio-tech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guilin Tourism Corp Ltd
SHE:000978
|
China | CN¥1.17 Billion |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥363.17 Million |
|
Xinjiang Tianshun Supply Chain Co Ltd
SHE:002800
|
China | CN¥523.26 Million |
|
Duni AB (publ)
PINK:DUNNF
|
USA | $4.02 Billion |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
USA | $10.37 Million |
|
Jacquet Metal Service SA
PA:JCQ
|
France | €786.00 Million |
|
Hudson Technologies Inc
NASDAQ:HDSN
|
USA | $73.06 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Shanghai Hile Bio-tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Hile Bio-tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Hile Bio-tech (2011–2024)
The table below shows the annual total liabilities of Shanghai Hile Bio-tech from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥123.65 Million | -74.40% |
| 2023-12-31 | CN¥482.96 Million | +19.77% |
| 2022-12-31 | CN¥403.25 Million | -52.94% |
| 2021-12-31 | CN¥856.90 Million | +3.92% |
| 2020-12-31 | CN¥824.54 Million | +16.34% |
| 2019-12-31 | CN¥708.72 Million | -1.95% |
| 2018-12-31 | CN¥722.81 Million | +37.20% |
| 2017-12-31 | CN¥526.83 Million | +11.02% |
| 2016-12-31 | CN¥474.55 Million | +71.31% |
| 2015-12-31 | CN¥277.01 Million | +188.62% |
| 2014-12-31 | CN¥95.98 Million | -4.19% |
| 2013-12-31 | CN¥100.17 Million | +7.97% |
| 2012-12-31 | CN¥92.78 Million | -5.61% |
| 2011-12-31 | CN¥98.29 Million | -- |